MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis

Table 2

Cox proportional hazard univariate regression analysis of miR-155-5p expression and clinicopathological variables for the prediction of CLL patients’ OS.

Covariate	HR	95% CI	value	BCa bootstrap (95% CI)	Bootstrap ( value)
miR-155-5p expression	1.80	1.19–2.72	0.006	1.08–3.00	0.007
miR-155-5p expression status
Negative	1.00
Positive	3.87	1.70–8.81	0.001	1.76–11.72	<0.001
Age	0.98	0.94–1.02	0.33	0.93–1.02	0.36
Binet stage (ordinal)	1.98	1.3–3.02	0.002	1.38–2.97	<0.001
Rai stage (ordinal)	1.50	1.14–1.98	0.004	1.16–2.02	0.002
Risk (ordinal)	3.01	1.52–5.94	0.002	1.85–5.29	<0.001
Serum LDH concentration
Normal	1.00
Elevated	1.61	0.76–3.41	0.22	0.74–3.66	0.21
CD38 expression status
Negative	1.00
Positive	3.57	1.68–7.58	<0.001	1.46–13.11	<0.001
IGHV mutational status
Mutated	1.00
Unmutated	2.78	1.18–6.55	0.020	1.19–7.99	0.013

CLL: chronic lymphocytic leukemia; OS: overall survival; HR: hazard ratio; CI: confidence interval; BCa: bias-corrected and accelerated; LDH: lactate dehydrogenase; IGHV: immunoglobulin heavy chain variable region.